NorthStar Medical Radioisotopes, LLC and IBA (Ion Beam Applications S.A., EURONEXT) announced a new contract in which NorthStar will purchase a third Rhodotron? TT300 HE electron beam accelerator from IBA. The accelerator will be exclusively used for the production of no-carrier added (n.c.a.) actinium-225 (Ac-225), an important therapeutic radioisotope that is in highly limited supply and for which no commercial-scale production technology currently exists. NorthStar previously purchased two Rhodotron? accelerators from IBA for its newly completed molybdenum-99 (Mo-99) production facility. The final stage of facility design is underway for NorthStar?s state-of-the-art Therapeutic Radioisotope production facility, which will be exclusively dedicated to Ac-225 production, with construction scheduled to begin in early 2022. Initial production of Ac-225 is planned for late 2023, and a Drug Master File will be submitted to the FDA in 2024. NorthStar?s proprietary process for the production of Ac-225 will use IBA?s Rhodotron? to enable commercial-scale n.c.a. Ac-225 production that is free of long-life radioactive byproducts associated with other production methods.